1. Home
  2. BVFL vs VTVT Comparison

BVFL vs VTVT Comparison

Compare BVFL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BV Financial Inc.

BVFL

BV Financial Inc.

HOLD

Current Price

$19.79

Market Cap

168.6M

Sector

Finance

ML Signal

HOLD

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$36.70

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BVFL
VTVT
Founded
1873
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
168.6M
148.7M
IPO Year
2023
2015

Fundamental Metrics

Financial Performance
Metric
BVFL
VTVT
Price
$19.79
$36.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
7.8K
45.7K
Earning Date
04-24-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
31.19
N/A
EPS
0.13
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$151.31
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.05
$14.00
52 Week High
$20.54
$44.00

Technical Indicators

Market Signals
Indicator
BVFL
VTVT
Relative Strength Index (RSI) 48.75 57.27
Support Level $19.27 $34.29
Resistance Level $19.91 $41.59
Average True Range (ATR) 0.44 2.23
MACD -0.04 0.77
Stochastic Oscillator 40.70 86.86

Price Performance

Historical Comparison
BVFL
VTVT

About BVFL BV Financial Inc.

BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: